Ciprofloxacin Sensitizes Cancer Cells to Ferroptosis via Mitochondrial Zn²⁺ Accumulation

Study Background and Research Question

Ferroptosis is a regulated, iron-dependent form of cell death defined by the accumulation of lipid peroxides, and has gained attention for its role in cancer therapy. While traditional chemotherapeutic strategies rely on apoptosis induction, the ability to modulate ferroptosis offers new avenues for selectively eliminating malignant cells. Ciprofloxacin (CFX), a fluoroquinolone antibiotic, is well-known for inhibiting bacterial DNA replication but has also demonstrated antitumor effects, including the induction of apoptosis and suppression of cancer cell proliferation. Previous work revealed that CFX can inhibit erastin-induced ferroptosis by stabilizing glutathione peroxidase 4 (GPX4), yet its influence on ferroptosis triggered by other inducers, such as RSL3, remained unclear. The central research question addressed by the reference study was whether CFX modulates RSL3-induced ferroptosis in tumor cells and, if so, through which molecular mechanism.

Key Innovation from the Reference Study

The reference paper presents a significant mechanistic advance by demonstrating that CFX, in combination with the ferroptosis inducer RSL3, synergistically enhances ferroptotic cell death in multiple cancer cell models. Unlike its GPX4-stabilizing, ferroptosis-inhibitory effect in the context of erastin treatment, CFX was found to promote RSL3-induced ferroptosis by driving mitochondrial Zn²⁺ accumulation. This process is orchestrated via a signaling cascade involving STING1 (stimulator of interferon genes cGAMP interactor 1) and caveolin-2 (CAV2), which together disrupt intracellular zinc homeostasis and facilitate mitochondrial import of Zn²⁺ via SLC25A25. The resulting elevation in mitochondrial reactive oxygen species (ROS) amplifies ferroptotic cell death, revealing a context-dependent, dual role for CFX in ferroptosis regulation. This duality has direct implications for the design of combination therapies that exploit regulated cell death pathways in cancer.

Methods and Experimental Design Insights

To interrogate the effect of CFX on RSL3-induced ferroptosis, the authors employed a multifaceted experimental approach encompassing antibiotic screening, live-cell imaging, molecular pathway analysis, and quantitative cell viability measurement. Key experimental highlights include:

• Systematic screening of antibiotics for potentiation of ferroptosis in tumor cells co-treated with RSL3.
• Genetic and pharmacological manipulation of STING1 and CAV2 to dissect pathway involvement.
• Measurement of mitochondrial and cytosolic Zn²⁺ concentrations using zinc-sensitive dyes and subcellular fractionation.
• Assessment of mitochondrial DNA stress and ROS production.
• Quantitative cell viability analysis, likely utilizing sensitive ATP-based assays, to precisely capture ferroptotic cell death kinetics.

These method choices allowed the authors to map the sequential signaling events from CFX-induced topoisomerase 2β inhibition to mitochondrial zinc overload and downstream ferroptotic death.

Protocol Parameters

• Ciprofloxacin treatment: Low-dose CFX applied in combination with RSL3 to cancer cell lines; dose and timing optimized for synergistic cell death detection.
• RSL3 induction: Applied at concentrations sufficient to inhibit GPX4 and induce ferroptosis; often used at 1–10 μM in standard protocols.
• Zn²⁺ detection: Employing zinc-specific fluorescent probes for live-cell imaging and mitochondrial fraction analysis.
• Viability assessment: ATP-based luminescent assays or equivalent methods, offering high sensitivity to detect rapid and early changes in cell viability.
• Pathway dissection: Use of siRNA or CRISPR-mediated knockdown of STING1 and CAV2 to validate pathway specificity.

Core Findings and Why They Matter

The study demonstrates that CFX exerts a context-specific, dual effect on ferroptosis depending on the upstream inducer and downstream pathway engagement. While previous work showed that CFX can stabilize GPX4 and suppress erastin-induced ferroptosis, the present findings reveal that in the presence of RSL3, CFX instead enhances ferroptotic death. This effect is critically dependent on the induction of mitochondrial DNA stress, which activates a STING1–CAV2 signaling cascade, causing zinc homeostasis disruption and mitochondrial Zn²⁺ accumulation. Elevated mitochondrial zinc then boosts ROS production, amplifying ferroptosis. These mechanistic insights clarify why ferroptosis is highly context-dependent and suggest that careful selection of combinatorial treatments (such as CFX with RSL3) may be required to achieve robust therapeutic effects in cancer. The findings may also explain discrepancies in ferroptosis sensitivity observed across different experimental models and underline the importance of mitochondrial stress and zinc signaling in cell death regulation.

Comparison with Existing Internal Articles

Several recent articles have explored advancements in cell viability measurement and ferroptosis quantification, particularly using luciferase luminescence detection platforms. For example, an internal review discusses how the Luminescent ATP Cell Viability Assay Kit I enables ultra-sensitive detection of cell viability changes during mitochondrial stress and ferroptosis studies. This is especially relevant given the reference paper’s focus on mitochondrial Zn²⁺ dynamics and rapid ferroptosis induction, where conventional colorimetric assays may lack the temporal resolution or sensitivity to detect early and subtle viability changes. Another article, focused on translational oncology, highlights the role of advanced luminescent ATP cell viability assays in reliably quantifying cytostatic and cytotoxic responses in complex cellular models. These internal resources collectively underscore the importance of assay selection and sensitivity in studying regulated cell death mechanisms, as shown in the reference study.

Limitations and Transferability

While the study offers compelling mechanistic insights, several limitations merit consideration. The context-dependent duality of CFX’s effect on ferroptosis emphasizes that results obtained in one model system or with one set of inducers may not extrapolate directly to others. The experiments were primarily performed in established cancer cell lines, which may not fully capture the heterogeneity of primary tumor environments or non-malignant tissues. In addition, while the role of mitochondrial Zn²⁺ accumulation was elegantly demonstrated, the broader physiological relevance and potential off-target effects of CFX require further exploration in in vivo models. Finally, the findings should be contextualized within the broader landscape of cell death research, where cross-talk between ferroptosis, apoptosis, and other death modalities can influence experimental outcomes.

Why this cross-domain matters, maturity, and limitations

This research bridges antibiotic pharmacology and cancer cell biology, revealing how a well-characterized antibacterial agent can modulate regulated cell death pathways in tumors. Such cross-domain insights highlight the potential for drug repurposing and underscore the interconnectedness of metabolic, redox, and signaling networks. However, the maturity of this approach is still at the preclinical stage, and translational applicability will depend on further validation in animal models and clinical samples.

Research Support Resources

For researchers aiming to reproduce or extend these mechanistic studies, robust and sensitive cell viability assays are indispensable—particularly for detecting early changes associated with mitochondrial stress and ferroptosis. Products such as the Luminescent ATP Cell Viability Assay Kit I (SKU: K2041) offer ultra-sensitive quantification of metabolically active cells via luciferase luminescence detection. This approach is well-suited for workflows investigating rapid cell viability changes in response to ferroptosis inducers or mitochondrial modulators. The ready-to-use format and high signal stability simplify experimental design, especially in time-course or low-cell-density applications. For more insights into assay selection and applications in ferroptosis quantification, researchers may consult internal articles such as this review of luciferase-based cell metabolism assays.